Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00456001 · ClinicalTrials.gov registry record
Heparin Induced Thrombocytopenia: Pharmacoeconomics
A clinical trial of Heparin Induced Thrombocytopenia (HIT), sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- 200
- Enrollment target
- 1
- Study location
NCT00456001 is a study of Heparin Induced Thrombocytopenia (HIT) that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 200 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00456001, a study of Heparin Induced Thrombocytopenia (HIT), has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
Patients at BWH receiving unfractionated heparin or enoxaparin who subsequently develop heparin induced thrombocytopenia will be identified via a computer generated report designed for the purposes of this study. Subsequently, we will compare the heparin induced thrombocytopenia rates associated with heparin and low molecular weight heparin usage as well as evaluate the economic and long-term clinical burden of heparin induced thrombocytopenia.
Conditions Studied
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2006-07 |
| Est. Completion | 2009-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00456001
The ClinicalTrials.gov registry entry for NCT00456001 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 200 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heparin Induced Thrombocytopenia (HIT) appearing as the primary indexed condition, and to 0 interventions.
NCT00456001 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00456001 about?
NCT00456001 is a clinical study titled "Heparin Induced Thrombocytopenia: Pharmacoeconomics". Patients at BWH receiving unfractionated heparin or enoxaparin who subsequently develop heparin induced thrombocytopenia will be identified via a computer generated report designed for the purposes of this study. Subsequently, we will compare the heparin induced thrombocytopenia rates associated wi...
What is the current status of trial NCT00456001?
This trial is currently completed. The enrollment target is 200 participants. The study started on 2006-07. Estimated completion is 2009-01.
What conditions does trial NCT00456001 study?
This clinical trial studies the following conditions: Heparin Induced Thrombocytopenia (HIT).
Who is sponsoring clinical trial NCT00456001?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00456001 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.